FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044804580> ?p ?o ?g. }

• W2044804580 endingPage "466" @default.
• W2044804580 startingPage "458" @default.
• W2044804580 abstract "MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis.BackgroundAlthough inflammation and apoptosis are known to play important roles in cisplatin nephrotoxicity, the exact intracellular signaling mechanisms are not well understood. Recent reports that extracellular signal-regulated kinase (ERK1/2) pathway mediates cisplatin-induced caspase activation and apoptosis in cultured renal tubular cells led us to investigate the effect of MAPK/ERK kinase (MEK) inhibitor, an immediate upstream of ERK1/2 in cisplatin-induced acute renal failure (ARF) in mice.MethodsThe effect of MEK/ERK1/2 inhibition on kidney tumor necrosis factor-α (TNF-α (gene expression, inflammation, the activation of tissue caspases, and apoptosis were examined in addition to its effects on renal function and histology in cisplatin-induced ARF in mice.ResultsPretreatment of MEK inhibitor, U0126, decreased ERK1/2 phosphorylation following cisplatin administration with significant functional and histologic protection. This beneficial effect was accompanied by decrease in TNF-α gene expression level and inflammation, as well as in caspase 3 activity and apoptosis.ConclusionThese data provide evidence that ERK1/2 pathway functions as an upstream signal for TNF-α–mediated inflammation and caspase 3–mediated apoptosis in cisplatin-induced ARF in mice and suggest that ERK1/2 can be a novel therapeutic target in cisplatin nephrotoxicity. MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis. Although inflammation and apoptosis are known to play important roles in cisplatin nephrotoxicity, the exact intracellular signaling mechanisms are not well understood. Recent reports that extracellular signal-regulated kinase (ERK1/2) pathway mediates cisplatin-induced caspase activation and apoptosis in cultured renal tubular cells led us to investigate the effect of MAPK/ERK kinase (MEK) inhibitor, an immediate upstream of ERK1/2 in cisplatin-induced acute renal failure (ARF) in mice. The effect of MEK/ERK1/2 inhibition on kidney tumor necrosis factor-α (TNF-α (gene expression, inflammation, the activation of tissue caspases, and apoptosis were examined in addition to its effects on renal function and histology in cisplatin-induced ARF in mice. Pretreatment of MEK inhibitor, U0126, decreased ERK1/2 phosphorylation following cisplatin administration with significant functional and histologic protection. This beneficial effect was accompanied by decrease in TNF-α gene expression level and inflammation, as well as in caspase 3 activity and apoptosis. These data provide evidence that ERK1/2 pathway functions as an upstream signal for TNF-α–mediated inflammation and caspase 3–mediated apoptosis in cisplatin-induced ARF in mice and suggest that ERK1/2 can be a novel therapeutic target in cisplatin nephrotoxicity." @default.
• W2044804580 created "2016-06-24" @default.
• W2044804580 creator A5020078138 @default.
• W2044804580 creator A5022267419 @default.
• W2044804580 creator A5052279132 @default.
• W2044804580 creator A5064681966 @default.
• W2044804580 creator A5082260479 @default.
• W2044804580 date "2005-02-01" @default.
• W2044804580 modified "2023-10-13" @default.
• W2044804580 title "MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis" @default.
• W2044804580 cites W1611610664 @default.
• W2044804580 cites W1965916534 @default.
• W2044804580 cites W1966110021 @default.
• W2044804580 cites W1969791922 @default.
• W2044804580 cites W1973186805 @default.
• W2044804580 cites W1976680355 @default.
• W2044804580 cites W1976754856 @default.
• W2044804580 cites W1976768241 @default.
• W2044804580 cites W1977721476 @default.
• W2044804580 cites W1996886208 @default.
• W2044804580 cites W2012726316 @default.
• W2044804580 cites W2015746497 @default.
• W2044804580 cites W2016721255 @default.
• W2044804580 cites W2024004416 @default.
• W2044804580 cites W2029691673 @default.
• W2044804580 cites W2038876417 @default.
• W2044804580 cites W2046640619 @default.
• W2044804580 cites W2051916700 @default.
• W2044804580 cites W2061430098 @default.
• W2044804580 cites W2065259546 @default.
• W2044804580 cites W2067265129 @default.
• W2044804580 cites W2070564037 @default.
• W2044804580 cites W2079254943 @default.
• W2044804580 cites W2088106137 @default.
• W2044804580 cites W2092557822 @default.
• W2044804580 cites W2103379588 @default.
• W2044804580 cites W2110376874 @default.
• W2044804580 cites W2116568010 @default.
• W2044804580 cites W2145407987 @default.
• W2044804580 cites W2151302623 @default.
• W2044804580 cites W2157388811 @default.
• W2044804580 cites W4240717991 @default.
• W2044804580 cites W4250210754 @default.
• W2044804580 doi "https://doi.org/10.1111/j.1523-1755.2005.67102.x" @default.
• W2044804580 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15673293" @default.
• W2044804580 hasPublicationYear "2005" @default.
• W2044804580 type Work @default.
• W2044804580 sameAs 2044804580 @default.
• W2044804580 citedByCount "205" @default.
• W2044804580 countsByYear W20448045802012 @default.
• W2044804580 countsByYear W20448045802013 @default.
• W2044804580 countsByYear W20448045802014 @default.
• W2044804580 countsByYear W20448045802015 @default.
• W2044804580 countsByYear W20448045802016 @default.
• W2044804580 countsByYear W20448045802017 @default.
• W2044804580 countsByYear W20448045802018 @default.
• W2044804580 countsByYear W20448045802019 @default.
• W2044804580 countsByYear W20448045802020 @default.
• W2044804580 countsByYear W20448045802021 @default.
• W2044804580 countsByYear W20448045802022 @default.
• W2044804580 countsByYear W20448045802023 @default.
• W2044804580 crossrefType "journal-article" @default.
• W2044804580 hasAuthorship W2044804580A5020078138 @default.
• W2044804580 hasAuthorship W2044804580A5022267419 @default.
• W2044804580 hasAuthorship W2044804580A5052279132 @default.
• W2044804580 hasAuthorship W2044804580A5064681966 @default.
• W2044804580 hasAuthorship W2044804580A5082260479 @default.
• W2044804580 hasBestOaLocation W20448045801 @default.
• W2044804580 hasConcept C126189478 @default.
• W2044804580 hasConcept C126322002 @default.
• W2044804580 hasConcept C134018914 @default.
• W2044804580 hasConcept C17991360 @default.
• W2044804580 hasConcept C184235292 @default.
• W2044804580 hasConcept C185592680 @default.
• W2044804580 hasConcept C190283241 @default.
• W2044804580 hasConcept C203014093 @default.
• W2044804580 hasConcept C2776694085 @default.
• W2044804580 hasConcept C2776914184 @default.
• W2044804580 hasConcept C2778239845 @default.
• W2044804580 hasConcept C2780091579 @default.
• W2044804580 hasConcept C502942594 @default.
• W2044804580 hasConcept C51551487 @default.
• W2044804580 hasConcept C55493867 @default.
• W2044804580 hasConcept C57074206 @default.
• W2044804580 hasConcept C62478195 @default.
• W2044804580 hasConcept C71924100 @default.
• W2044804580 hasConcept C86803240 @default.
• W2044804580 hasConcept C95444343 @default.
• W2044804580 hasConcept C98274493 @default.
• W2044804580 hasConceptScore W2044804580C126189478 @default.
• W2044804580 hasConceptScore W2044804580C126322002 @default.
• W2044804580 hasConceptScore W2044804580C134018914 @default.
• W2044804580 hasConceptScore W2044804580C17991360 @default.
• W2044804580 hasConceptScore W2044804580C184235292 @default.
• W2044804580 hasConceptScore W2044804580C185592680 @default.
• W2044804580 hasConceptScore W2044804580C190283241 @default.
• W2044804580 hasConceptScore W2044804580C203014093 @default.
• W2044804580 hasConceptScore W2044804580C2776694085 @default.

• next